Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

Cancers, Vol. 11, Pages 2024: Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma:

Cancers, Vol. 11, Pages 2024: Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

Cancers doi: 10.3390/cancers11122024

Authors:
Naoki Hosen


CD19 Chimeric antigen receptor (CAR) T cell therapy has been shown to be effective for B cell leukemia and lymphoma. Many researchers are now trying to develop CAR T cells for various types of cancer. For multiple myeloma (MM), B-cell maturation antigen (BCMA) has been recently proved to be a promising target. However, cure of MM is still difficult, and several other targets, for example immunoglobulin kappa chain, SLAM Family Member 7 (SLAMF7), or G-protein coupled receptor family C group 5 member D (GPRC5D), are being tested as targets for CAR T cells. We also reported that the activated integrin β7 can serve as a specific target for CAR T cells against MM, and are preparing a clinical trial. In this review, we summarized current status of CAR T cell therapy for MM and discussed about the future perspectives.